KJHP
ALXN

K.J. Harrison & Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

K.J. Harrison & Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$209K – 202
2018
Q3 		$209K Buy
+1,500
New +$188K 0.05% 176

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

K.J. Harrison & Partners's ALXN Position: Q4 2018 in Review

K.J. Harrison & Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 1,500 shares — an estimated $209K sold.

K.J. Harrison & Partners first reported a position in ALXN in Q3 2018 and held it in 1 quarter. The position peaked at $209K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • K.J. Harrison & Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • K.J. Harrison & Partners sold 1,500 Alexion Pharmaceuticals shares in Q4 2018, an estimated $209K.
  • K.J. Harrison & Partners first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • K.J. Harrison & Partners's Alexion Pharmaceuticals position peaked at $209K in Q3 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on K.J. Harrison & Partners's 13F filing for Q4 2018, filed 24 Jan 2019.